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Abstract
Microcarriers are widely used for the large-scale culture of attachment-dependent cells with increased cell densities
and, ultimately, higher product yield. In these processes, the specific culture conditions can affect the quality of the
product, which is closely related to its glycosylation pattern. Furthermore, the lack of studies in the area reinforces
the need to better understand the effects of microcarrier culture in product glycosylation. Consequently, in this
work, the glycosylation profile of a monoclonal antibody (mAb) produced by adherent CHO-K1 cells grown in
Cytodex 3 was evaluated under different conditions, and compared to that obtained of typical adherent cultures. It
was found that microcarrier cultures result in a glycosylation profile with different characteristics from T-flask
cultures, with a general increase in galactosylation and decrease in fucosylation levels, both with a potentially
positive impact on mAb activity. Sialylation also varied but without a general tendency. This study then showed
that the specific culture conditions used in microcarrier culture influence the mAb glycan profile, and each
functional element (galactose, core fucose, sialic acid) is independently affected by these conditions. In particular,
great reductions of fucosylation (from 79 to 55%) were obtained when using half volume at inoculation, and
notable decreases in sialylation (from 23 to 2%) and glycoform heterogeneity (from 20 to 11 glycoforms) were
observed for shake flask culture, potentially associated with the improved cell densities achieved in these culture
vessels.
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Background
Microcarrier systems are the most well-known technology
for the large-scale culture of adherent cells in biotechnol-
ogy (Chu and Robinson 2001; Kong et al. 1999; Ziao et al.
2002). Indeed, several types of microcarriers have been
successfully used for the production of viral vaccines
(Berry et al. 1999; Butler et al. 2000; Mendonça et al. 1993;
Wu and Huang 2002; Wu et al. 2002) and recombinant
proteins (Blüml 2007; Cosgrove et al. 1995; Hu et al. 2000;
Wang et al. 2002; Wang and Ouyang 1999), in conse-
quence of an improved surface area available for cell adhe-
sion that results in higher cell density and product yield
(Blüml 2007; Hirtenstein et al. 1980; Rudolph et al. 2008;
Schürch et al. 1992; Van Wezel 1967). Generally, micro-
carriers can be divided into microporous (e.g. Cytodex)
and macroporous (e.g. CultiSpher, Cytoline, Cytopore),
according to the size of the porous, which allow cell
growth on the surface or on both surface and inner
spaces, respectively (Almgren et al. 1991; Butler 1996;
Nilsson et al. 1986; Ozturk and Hu 2006; Spearman et al.
2005; Yokomizo et al. 2004).
The characteristics of the microcarriers are important
for the success of the culture (Butler 1996; Ozturk and Hu
2006), but other factors must be considered, such as the
size and type of culture vessel (Wang et al. 2002; Wu et al.
1998), and the culture environment (Nam et al. 2008; Ng
et al. 1996). Furthermore, it is also important to recognize
that the specific conditions of the culture can influence
product quality, through effects on protein glycosylation.
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Indeed, it has become evident that glycosylation plays
critical roles in protein effectiveness in vivo (Jenkins and
Curling 1994), and the ability to perform this post-
translational modification is a major reason for the
current choice of mammalian cells as hosts for recom-
binant therapeutic protein production (Nam et al. 2008).
It is therefore essential to ensure that glycosylation of
recombinant proteins in microcarrier culture is consist-
ent with the desired product (Spearman et al. 2005).
However, to date, there are limited studies examining
the effects of changing between adherent, suspension,
and microcarrier cultures on glycosylation of the recom-
binant product (Nam et al. 2008). Furthermore, the few
studies performed typically compare microcarrier culture
to culture in suspension (Hooker et al. 2007; Wang et al.
2002; Watson et al. 1994), and not to the normal adher-
ent cell culture conditions, and have shown results that
seem to be specific to the type of cell, product, and
microcarrier used. For example, increased sialylation was
found in Cytodex culture for recombinant human tissue
kallikrein production (Watson et al. 1994) and in Cyto-
line culture of Chinese hamster ovary (CHO) cells in a
fluidized bed bioreactor for interferon-γ production
(Hooker et al. 2007), while no differences were found in
human recombinant erythropoietin (EPO) produced by
CHO cells in fluidized bed bioreactor cultures with
Cytoline (Wang et al. 2002).
In an effort to elucidate the effects of microcarrier cul-
ture on protein glycosylation, the present work evaluates
the glycan profile of a monoclonal antibody (mAb), with
application on cancer therapy, produced by CHO-K1
cells grown in microcarriers. Different culture conditions
are assessed to determine their influence on mAb glyco-
sylation, particularly on the galactosylation, fucosylation
and sialylation levels, with discussion of their potential
impact on the biological effectiveness of the mAb. Add-
itionally, the glycosylation profiles obtained in microcar-
rier cultures are compared to those of adherent culture
in common culture vessels (T-flasks).
Results and discussion
An appropriate glycosylation of recombinant proteins,
particularly mAbs, is important for their biological activ-
ity and clinical efficacy (Spearman et al. 2005). It is
therefore essential to ensure that glycosylation in micro-
carrier cultures is consistent with the desired product. In
this study, mAb-producing CHO-K1 cells were cultured
in microporous Cytodex 3 carriers, under different cul-
ture conditions to evaluate their impact on the glycosy-
lation profile of the mAb. Additionally, the glycosylation
obtained in microcarrier cultures was compared to that
of normal adherent culture conditions in T-flasks. The
profiles obtained by normal phase HPLC are shown in
Figure 1, and the glucose unit (GU) values and tentative
structure assignments of the peaks identified, as well as
the relative (%) peak area obtained in each assay, are
shown in Table 1. Glycans found in all conditions are
mainly complex biantennary structures with a high degree
of heterogeneity, containing different terminal sugars, in-
cluding sialic acid (S), galactose (G), N-acetylglucosamine
(A) and core fucose (F). However, differences can be found
between the microcarrier cultures and the typical adherent
culture in T-flask in the prevalence of certain glycans, par-
ticularly of the most typical IgG1 structures: FA2 (peak 4),
FA2G1 (peaks 8 and 9, corresponding to α1-6 and α1-
3-linked fucose, respectively), and FA2G2 (peak 11).
Indeed, FA2 and FA2G1 (α1-6) show a general tendency
to decrease, while FA2G1 (α1-3) and FA2G2 levels in-
crease in microcarrier cultures.
The reduction of the prevalence of these main struc-
tures in microcarrier culture is obviously accompanied
by an increase in the remaining structures, particularly
of core fucosylated disialylated glycans such as FA2G2S2
(peak 19) and FA3G3S2 (peak 21), and of A1 (peak 1)
and A1G1 (peak 3).
The changes on the mAb glycosylation profile observed
between the T-flask and the microcarrier cultures may re-
sult from the creation of a different microenvironment for
the cells in the microcarriers (Spearman et al. 2005). This
may impact glycosylation directly or through variations
caused on cell growth characteristics and mAb productiv-
ity, such as the ones observed in this study. Effectively, it
is clear from Table 2 that microcarriers provide variable
cell concentrations, but mAb productivities are always
enhanced when compared to T-flasks. Furthermore, it is
known that CHO cells produce enzymes such as sialidase,
beta-galactosidase, and fucosidase that can accumulate
extracellularly in culture and potentially lead to extracellu-
lar modifications of the glycans (Gramer and Goochee
1993). By affecting cell characteristics, microcarrier cul-
ture may also influence the production of such enzymes
and potentially interfere with glycosylation.
Furthermore, microcarrier cultures were performed
under rocking conditions, which were not present in the
typical T-flask cultures, and which may also be a factor
leading to the differences found between the glycosyla-
tion profile of the mAb obtained in these two types of
cultures.
Several studies have focused on the effect of specific
elements of the glycan profile on the effector function of
glycosylated proteins. Known as functional elements,
these include galactose, core fucose, and sialic acid, and
have been shown to influence antibody-dependent cellu-
lar cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC). In fact higher levels of galactosyla-
tion (Abès and Teillaud 2010; Hodoniczky et al. 2005;
Jefferis and Lund 1997; Serrato et al. 2007), reduced core
fucosylation (Shields et al. 2002; Shinkawa et al. 2003;
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Sibéril et al. 2006) or reduced sialylation (Anthony and
Ravetch 2010; Anthony et al. 2008; Kaneko et al. 2006;
Scallon et al. 2007) are suggested to enhance the clinical
efficacy of mAbs that exert their therapeutic effect by
ADCC and CDC mediated killing, such as those used
for cancer treatment, including the mAb here assessed.
This is particularly relevant for core fucosylation, whose
absence can improve ADCC activity by up to 100-fold
(Shields et al. 2002).
The relative percentages of the main functional ele-
ments of the mAb produced under the different culture
conditions of this study are shown in Table 3. In a first
assessment it is possible to detect a general increase of
galactosylation (mainly digalacto (G2) and trigalacto
(G3) structures) and decrease of fucosylation in micro-
carrier cultures compared to T-flasks, both having a po-
tential positive effect on mAb activity. On the other
hand, although also diverging from the T-flask cultures,
the levels of sialylation in the microcarrier assays are
more variable, without showing a common tendency,
which indicates that this element may be more suscep-
tible to the culture conditions assayed. As mentioned
above, it has been shown that CHO cells produce an
extracellular sialidase capable of modifying the sialic acid
content of glycoproteins (Gramer and Goochee 1993),
and the production/accumulation of this enzyme may be
influenced by culture conditions, therefore affecting the
degree of sialylation. Additionally, it should be noted
that the reported degree of sialylation in human IgG has
been below 20% (Arnold et al. 2007; Pučić et al. 2011;
Serrato et al. 2007), but some of the microcarrier cul-
tures showed superior levels (e.g. CY2), mainly due to a
higher prevalence of disialylated (S2) structures, both
digalacto (S2G2) and trigalacto (S2G3), with potential
negative effects on mAb activity by reducing ADCC.
Hypergalactosylation has been associated with low cell
densities in previous studies (Kumpel et al. 1994), but
there was no correlation found in this work between the
higher levels of mAb galactosylation and the cell dens-
ities achieved (Table 2) in microcarrier cultures. For core
CY1
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Figure 1 N-glycosylation profile of the monoclonal antibody produced by CHO-K1 cells cultured under different culture conditions:
T-flask; CYi – Cytodex 3 in vented conical tubes; CYS – Cytodex 3 in shake flask.
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fucose, it is interesting to note that in addition to the re-
duction observed in the total levels of fucosylation, varia-
tions are also found in the ratio of agalacto:monogalacto:
digalacto:trigalacto (FG0:FG1:FG2:FG3) structures, with a
general switch from the FG0 prevalence in T-flask cultures
to a FG1 prominence in microcarriers. In both cases, the
divergences observed between microcarrier and T-flask
cultures may have been caused by the use of rocking in
the former.
Furthermore, it should be noted that the potentially
better levels (in terms of mAb activity) of each of the
functional elements are not obtained in the same condi-
tions. For example, in terms of galactosylation, mAb
with improved characteristics (higher galactose) was pro-
duced in CY2; while for fucosylation, the best quality
mAb (less core fucose) was obtained in CY5; and for
sialylation, the lower and best levels were obtained in
CY1, CY7, and CYS.
It has been suggested that increases in productivity,
such as the ones observed in the microcarrier cultures,
may potentially lead to decreased effectiveness of recom-
binant proteins (Nam et al. 2008). However, in this work,
the increased productivities of microcarrier cultures
(Table 2) do not seem to correlate with a lower quality
of the mAb.
In a more specific analysis, the different conditions
evaluated for the microcarrier cultures were considered.
Rocking speed influences the mAb glycosylation profile,
but this effect is highly dependent on the rocking meth-
odology. For example, when using pulse/continuous
Table 1 Data of mean glucose unit (GU) value, tentative structure assignment, and relative (%) area of the peaks of
the monoclonal antibody produced by CHO-K1 cells under different culture conditions: T-Flask; CYi – Cytodex 3 in
vented conical tubes; CYS – Cytodex 3 in shake flask
% Area
Peak Mean GUa Tentative assignment T-Flask CY1 CY2 CY3 CY4 CY5 CY6 CY7 CYS
1 4.9 ± 0.01 A1 2.09 3.33 3.54 3.03 3.76 10.54 4.48 1.77 6.10
2 5.33 ± 0.01 FA1 / A2 2.01 1.75 1.59 2.54 3.03 3.40 1.56 1.74 3.32
3 5.66 ± 0.01 A1G1 - 5.69 5.76 5.15 5.31 14.16 5.70 - 8.60
4 5.80 ± 0.01 FA2 40.99 22.01 16.59 20.59 21.24 16.93 16.87 30.92 27.57
5 6.18 ± 0.01 M5 / A2G1 1.50 1.93 1.68 2.44 2.39 3.13 1.77 2.45 2.82
6 6.31 ± 0.04 A2G1[6] - 1.61 1.19 1.97 2.55 - 1.36 1.29 4.86
7 6.42 ± 0.01 A2G1[3] - 2.34 2.49 1.82 1.88 6.22 2.77 - -
8 6.64 ± 0.01 FA2G1[6] 23.52 20.74 15.60 16.12 17.10 13.20 15.62 25.59 23.46
9 6.75 ± 0.01 FA2G1[3] 9.11 15.18 10.53 11.45 12.98 7.33 11.77 13.23 9.85
10 7.15 ± 0.02 A2G2 / M6 1.65 2.59 2.15 1.94 2.37 3.25 2.72 1.81 2.59
11 7.59 ± 0.01 FA2G2 8.40 14.65 11.74 9.86 11.60 7.76 12.61 13.43 9.27
12 7.97 ± 0.01 FA2G1S1 2.73 2.16 2.18 1.91 1.83 2.86 2.54 1.72 1.56
13 8.46 ± 0.01 A2G2S1 0.91 1.29 2.12 2.03 1.58 2.44 1.98 1.09 -
14 8.70 ± 0.02 FA2G2S1[3] - - - - - 0.85 1.08 - -
15 8.88 ± 0.01 FA2G2S1[6] 0.98 1.26 2.38 2.19 1.71 0.78 1.68 1.06 -
16 9.17 ± 0.02 A2G2S2[3] - - - - - - - - -
17 9.36 A3G3S1 - - - - - - - - -
18 9.58 ± 0.01 A2G2S2[6] 1.99 0.73 3.70 2.31 1.88 1.95 2.64 0.94 -
19 10.03 ± 0.01 FA2G2S2 0.95 1.25 6.43 5.66 3.17 2.84 4.94 1.54 -
20 10.22 ± 0.00 A3G3S2 - - 1.18 1.11 0.54 - 1.04 - -
21 10.43 ± 0.01 FA3G3S2[3] 1.14 1.49 4.56 5.85 3.73 2.35 5.08 1.40 -
22 10.56 ± 0.01 FA3G3S2[6] - - 2.05 - - - - - -
23 10.68 FA3G3S2[3,6] 0.92 - - - - - - - -
24 10.93 ± 0.04 A3G3S3 0.84 - 2.54 2.01 1.34 - 1.79 - -
25 11.12 ± 0.01 A3G3S3[3] - - - - - - - - -
26 11.43 FA3G3S3 0.27 - - - - - - - -
Main structures 82.02 72.58 54.46 58.02 62.92 45.22 56.87 83.17 70.15
Other structures 17.98 27.42 45.54 41.96 37.07 54.77 43.13 16.81 29.85
The main structures are noted in bold.
aAverage of the GU value of all samples containing the peak.
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rocking methodology, 60 rpm enables the production of
mAbs with lower levels of sialylation (reduced S2
structures) compared to 40 rpm (CY1 versus CY3),
which are potentially more effective through ADCC.
However, using a continuous rocking (CY2 versus CY4),
these observations are reversed, and 40 rpm (CY4)
appears as the advantageous rocking speed. There seems
to be no correlation between these results and the cell
concentrations and productivities achieved in these
assays (Table 2). Nevertheless, the combination of rock-
ing speed and mechanism should be considered for
mAb quality.
It is mentioned in the literature that the success of the
microcarrier culture is dependent on the initial colonization
of the microcarriers with the cells (Blüml 2007; Butler
1996; Voigt and Zintl 1999), so the culture conditions
during the first hours of culture should be optimized to
improve this initial cell adhesion. In this work, two
parameters that have been related to the efficiency of
initial cell adhesion were assessed, namely the rocking
methodology used for the first six hours of culture and
the volume of the culture at inoculation.
Table 2 Data of average cell concentration and
productivity of monoclonal antibody-producing
CHO-K1 cells cultured in different conditions: T-flask;
CYi – Cytodex 3 in vented conical tubes; CYS – Cytodex 3
in shake flask
Assay Av. viable cell conc. qmAb
(x105 cells/mL) (pg/cell/day)
T-flask 8.51 ± 0.06 0.21 ± 0.05
CY1 6.86 ± 1.06 2.57 ± 1.38
CY2 16.02 ± 1.98 0.84 ± 0.35
CY3 3.73 ± 0.63 3.89 ± 1.17
CY4 6.21 ± 0.62 2.16 ± 0.94
CY5 7.63 ± 0.76 1.75 ± 0.66
CY6 18.51 ± 1.08 1.26 ± 0.99
CY7 10.25 ± 0.73 1.51 ± 0.30
CYS 104.1 ± 6.00 1.86 ± 0.58
Table 3 Galactose, core fucose and sialic acid composition of the monoclonal antibody produced by CHO-K1 cells
during microcarrier culture in different conditions: T-flask; CYi - Cytodex 3 in vented conical tubes; CYS - Cytodex 3 in
shake flask
% Area
Glycan structures T-flask CY1 CY2 CY3 CY4 CY5 CY6 CY7 CYS
Total peaks 17 17 20 19 19 17 20 15 11
Agalactosylated (G0) 46.67 29.35 23.64 28.35 30.41 34.06 25.16 36.56 39.70
Galactosylated (G1+G2+G3) 53.34 70.65 76.37 71.63 69.58 65.93 74.85 63.42 60.31
Monogalactosylated (G1) 36.11 48.69 38.59 39.64 42.85 45.34 40.65 43.06 49.74
Digalactosylated (G2) 14.06 20.48 27.45 23.02 21.13 18.25 26.29 18.97 10.57
Trigalactosylated (G3) 3.17 1.49 10.33 8.97 5.61 2.35 7.91 1.40 0.00
Core fucosylated (F) 89.01 78.74 72.06 73.63 73.36 54.90 72.19 88.89 71.71
Core fucosylated agalactosylated (FG0) 40.99 22.01 16.59 20.59 21.24 16.93 16.87 30.92 27.57
Core fucosylated monogalactosylated (FG1) 35.36 38.08 28.31 29.48 31.91 23.39 29.93 40.54 34.87
Core fucosylated digalactosylated (FG2) 10.33 17.16 20.55 17.71 16.48 12.23 20.31 16.03 9.27
Core fucosylated trigalactosylated (FG3) 2.33 1.49 6.61 5.85 3.73 2.35 5.08 1.40 0.00
Sialylated (S1+S2+S3) 10.73 8.18 27.14 23.07 15.78 14.07 22.77 7.75 1.56
Monosialylated (S1) 4.62 4.71 6.68 6.13 5.12 6.93 7.28 3.87 1.56
Disialylated (S2) 5.00 3.47 17.92 14.93 9.32 7.14 13.70 3.88 0.00
Trisialylated (S3) 1.11 0.00 2.54 2.01 1.34 0.00 1.79 0.00 0.00
Monosialylated monogalactosylated (S1G1) 2.73 2.16 2.18 1.91 1.83 2.86 2.54 1.72 1.56
Monosialylated digalactosylated (S1G2) 1.89 2.55 4.50 4.22 3.29 4.07 4.74 2.15 0.00
Monosialylated trigalactosylated (S1G3) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Disialylated digalactosylated (S2G2) 2.94 1.98 10.13 7.97 5.05 4.79 7.58 2.48 0.00
Disialylated trigalactosylated (S2G3) 2.06 1.49 7.79 6.96 4.27 2.35 6.12 1.40 0.00
Trisialylated trigalactosylated (S3G3) 1.11 0.00 2.54 2.01 1.34 0.00 1.79 0.00 0.00
Complex glycans 98.43 97.74 98.09 97.81 97.62 96.81 97.76 97.87 97.30
High mannose 1.58 2.26 1.92 2.19 2.38 3.19 2.25 2.13 2.71
The major structures are marked in bold.
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Regarding the rocking methodology, it was found that
this culture parameter affects the glycosylation profile,
but diverges with the concentration of cell inoculum
used. Indeed, when using 2 × 105 cells/mL (CY1 versus
CY2), continuous rocking resulted in increased levels of
sialylation, mainly due to a higher presence of S2 struc-
tures, which potentially results in a less efficient mAb
due to a decreased ADCC activity. However, when using
a cell inoculum of 4 × 105 cells/mL (CY6 versus CY7),
the continuous rocking leads to a mAb with lower galac-
tosylation and sialylation, and higher fucosylation, whose
biological impact is difficult to predict due to the oppos-
ite effects of these functional elements, although a
decline of mAb effectiveness would be expected due to
the greater impact of fucosylation on mAb functionality.
Nevertheless, the combination of rocking methodology
at the beginning of the culture and concentration of cell
inoculum seems to be important for mAb quality.
Concerning the culture volume, the use of total
(5 mL) or half (2.5 mL) volume was tested (CY1 versus
CY5), with half (CY5) leading to a higher sialylation
(mainly due to increased S2) and to a great reduction in
the levels of fucosylation. Due to the known strong im-
pact of fucosylation on IgG activity through ADCC
(Shields et al. 2002), it is expected that the positive
effects associated with its reduction in these conditions
will surpass the negative effects of an increased sialyla-
tion, and result in a mAb with improved activity. The
use of different volumes at inoculation may affect the
microenvironment of the cells and therefore influence
glycosylation. Furthermore, although it has been sug-
gested that the use of half volume during the initial
hours of culture may improve cell adhesion and conse-
quently the final cell and product yields, such effect was
not observed in this study.
In addition to the functional elements already dis-
cussed, other less abundant glycoforms may also have an
important effect on the biological activity of therapeutic
IgGs. The presence of high mannose structures, for ex-
ample, has been associated with reduced ADCC and
CDC (Kanda et al. 2007), as well as with a rapid IgG
clearance from serum (Abès and Teillaud 2010). In this
study, the levels of high mannose are, in general, slightly
increased in microcarrier cultures (particularly for CY5).
The influence of the culture vessel on the glycosylation
profile of the mAb produced by CHO cells in microcar-
riers was also considered in this work, by comparing
vented conical tubes with shake flasks. The culture ves-
sel was highly influential particularly in the sialylation
levels of the mAb, which abruptly decreased to practic-
ally absent sialylation in shake flasks, predicting a posi-
tive outcome on mAb biological activity. Additionally,
shake flasks seem to provide a less heterogeneity of gly-
coforms, as demonstrated by the lowest number of peaks
obtained (11 peaks, Table 3). Since cell concentrations
are highly improved in shake flasks when compared to
the vented conical tube cultures, it is possible that these
improved levels, or the factors that led to them (e.g. better
oxygenation and mass transfer), have caused these modifi-
cations on sialylation and heterogeneity.
Some additional cultures were performed with a differ-
ent type of microcarrier, specifically the macroporous Cul-
tiSpher-S, for effects of comparison (data not shown). The
global influence of CultiSpher-S cultures on glycosylation,
in comparison with T-flask cultures, was similar to that
previously observed with Cytodex 3, causing a general re-
duction on the percentage of main structures, an increase
of galactosylation, a slightly reduction of fucosylation, and
a variable effect on sialylation. Furthermore, two culture
variables tested with CultiSpher-S (initial culture volume
and culture vessel) also demonstrated effects on glycosyla-
tion similar to those of Cytodex 3 cultures. Of note is the
strong impact of the culture vessel on the glycosylation
profile obtained with both microcarrier cultures, with
shake flasks confirming to be the best option by decreas-
ing the heterogeneity of glycoforms and leading to re-
markable decreases of mAb sialylation with CultiSpher-S.
The cell densities achieved on these microcarriers were
also significantly improved in shake flasks, reinforcing the
possibility of this being the cause for the positive changes
observed in the glycosylation profile of the mAb.
Conclusions
An understanding of the role of culture conditions on gly-
cosylation is becoming increasingly important to ensure a
consistent quality of the product. In this study, the effect
of microcarrier culture and different culture conditions on
the glycosylation pattern of a mAb produced by CHO-K1
cells was evaluated. Higher levels of galactosylation (main
di- and trigalacto structures) and lower degrees of fucosy-
lation were found in mAb produced in microcarriers
when compared to the typical T-flask culture, both poten-
tially improving the mAb effectiveness. On the other
hand, sialylation was found to be highly variable without a
specific tendency. Furthermore, contrary to what has been
suggested, the increased productivities obtained in micro-
carrier cultures did not correlate with a lower quality of
the mAb. On the other hand, the fact that microcarrier
cultures are performed under rocking conditions, as
opposed to T-flask cultures, and the possible creation of
specific microenvironments in the microcarriers may be a
cause for the divergences found between them in the gly-
cosylation profile of the mAb produced.
All the culture conditions assessed in microcarrier cul-
ture led to modifications on the mAb glycan profile,
with each of the functional elements (galactose, core
fucose and sialic acid) being divergently affected by these
conditions. In particular, the choice of the culture vessel
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appears to have a strong influence in mAb sialylation,
with great and desirable reductions achieved in shake
flask cultures. This is potentially related to highly
improved cell densities achieved in these vessels, which
may have also been the cause for a reduction of the gly-
coform heterogeneity of the mAb.
Methods
Cell line and cell preparation
A CHO-K1 cell line (obtained from American Type Cul-
ture Collection) previously transfected for the production
of a recombinant human mAb (CAB051 from Biotecnol
SA, Lisbon, with application on cancer therapy) was used
(Costa et al. 2012). These cells were grown in Dulbecco’s
Modified Eagle Medium (DMEM, Sigma-Aldrich) sup-
plemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich) and 1 × hypoxanthine-aminopterin-thymidine
(HAT, Sigma-Aldrich), at 37°C and 5% CO2, in 75 cm
2
culture flasks (T-flasks). For the microcarrier cultures,
cells were detached after reaching 70–80% confluence,
and the concentration of the cell suspension adjusted to
the values needed for each assay.
Microcarrier preparation
The microporous Cytodex 3 (Sigma-Aldrich) was used
in this work, and prepared according to manufacturer
instructions. Briefly, the dry microcarriers were swollen
and hydrated in calcium- and magnesium-free phos-
phate buffered saline (Ca/Mg-free PBS, 137 mM sodium
chloride, 2.7 mM potassium chloride, 10 mM sodium
phosphate dibasic, and 2 mM potassium phosphate
monobasic, pH 7.4, Sigma-Aldrich) for at least 3 h at
room temperature, sterilized (121°C, 15 min, 15 psi),
and stored at 4°C. Prior to use, the sterilized microcar-
riers were washed twice with culture medium and once
with Ca/Mg-free PBS.
Microcarrier culture
Microcarrier cultures were initially performed in 50 mL
vented conical tubes (INOPAT) and later in 250 mL
shake flasks (Sigma-Aldrich).
In vented conical tubes, 5 mL cultures of CHO-K1
cells were performed with 3 g/L of Cytodex 3, and differ-
ent culture conditions were assessed, as described in
Table 4. All cultures were maintained at 37°C and 5%
CO2, in a support that ensured a fixed 30° inclination
angle, placed on an orbital rocking platform. The assays
using half the volume of medium at inoculation were
completed with the remaining volume after the first 6 h
of culture (considered the critical phase for initial cell
adhesion). For all assays, the medium was renewed daily
by replacing half of the culture volume with fresh
growth medium.
In shake flasks, cultures of 20 mL of CHO-K1 cells
were performed as described for the vented conical
tubes, with the exception of the 30° inclination.
Culture monitoring
Cell growth was monitored for T-flask and Cytodex 3
cultures. Cells were released from the microcarriers by
enzymatic digestion with trypsin (Sigma-Aldrich) and
enumerated in a hematocytometer with trypan blue stain-
ing (Sigma-Aldrich), for viability assessment. In microcar-
rier cultures, the cell concentration in the sample was
standardized with the number of microcarriers counted
microscopically in the sample, and the concentration of
cells per microcarrier (Ccell/microcarrier) determined accord-
ing to Equation 1.
Ccell=microcarrier ¼
Ncell=4ð Þ  104½   F  Vsample
Nmicrocarriers in sample
ð1Þ
Where Ncell is the total number of cells counted in the
hematocytometer, F the sample dilution factor, Vsample the
volume of the sample in mL, and Nmicrocarriers in sample the
total number of microcarriers counted in the sample.
The cell concentration in the culture (Ccell/mL) was
then determined according to Equation 2.
Ccell=mL ¼ Ccell=microcarrier  Cmicrocarriers=mL ð2Þ
Where Ccell/microcarrier is the cell concentration per
microcarrier, and Cmicrocarriers/mL is the microcarrier
Table 4 Conditions tested for the culture of monoclonal antibody-producing CHO-K1 cells in Cytodex 3 microcarriers
Assay Inoculum concentration (cells/mL) Rocking mechanism Rocking speed (rpm) Volume at inoculation Culture vessel
CY1 2×105 Pulse followed by continuousa 60 Total Vented conical tube
CY2 2×105 Continuous 60 Total Vented conical tube
CY3 2×105 Pulse followed by continuousa 40 Total Vented conical tube
CY4 2×105 Continuous 40 Total Vented conical tube
CY5 2×105 Pulse followed by continuousa 60 Half Vented conical tube
CY6 4×105 Pulse followed by continuousa 60 Total Vented conical tube
CY7 4×105 Continuous 60 Total Vented conical tube
CYS 4x105 Pulse followed by continuousa 60 Total Shake flask
a Pulse rocking (60 or 40 rpm for 1 min at each 30 min) during the first six hours of culture, followed by continuous rocking for the remaining time of culture.
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concentration in microcarriers per mL as obtained from
Equation 3.
Cmicrocarriers=mL ¼ Cmicrocarriers in g=mL
 Nmicrocarriers=g dry weight ð3Þ
Where Cmicrocarriers in g/mL is the concentration of
microcarriers used in the culture in grams of dry weight
per mL, and Nmicrocarriers/g dry weight is the approximate
number of microcarriers per gram of dry weight (data
provided by the manufacturer).
Antibody quantification
Cell productivity was assessed by enzyme linked im-
munosorbent assay (ELISA), following an optimized pro-
cedure of Biotecnol SA (Portugal). Briefly, dilutions of
the samples, a standard of known concentration, and a
quality control were added to 96 well plates previously
coated with capture antibody. After incubation for 2 h at
37°C, a detection antibody was added and the plates fur-
ther incubated for 2 h at room temperature. A 3,30,5,50-
Tetramethylbenzidine (TMB, Sigma-Aldrich) substrate
solution was then added and allowed to react for
10 min, at room temperature, the reaction stopped, and
the absorbance read at 450 nm. The concentration of
mAb (CmAb, in μg/mL) in each sample was determined
by Equation 4 and the productivity (qmAb, in pg/cell/day)
calculated according to Equation 5.






Where Abs450 is the absorbance read at 450 nm, a the
estimated response at zero concentration, b the slope
factor, c the mid-range concentration, d the estimated
response at infinite concentration (parameters deter-
mined using the R software, version 2.6.2, from the R
Foundation for Statistical Computing).




Where t is the time of production in days.
N-glycosylation analysis
The glycosylation profile of the mAb obtained from the
T-flask and microcarrier cultures at different conditions
was assessed.
IgG purification
Prior to IgG purification, samples were concentrated to
volumes of 200 μL using 15 mL spin concentrators of 5
kDa molecular weight cutoff (Agilent Technologies).
Then, the IgG from the concentrated samples was puri-
fied with Protein A spin plates (Thermo Scientific)
according to manufacturer instructions, with slight
modifications. Briefly, the wells of a spin plate were
equilibrated with Binding Buffer (phosphate buffered
saline, pH 7.2), sample dilutions (50% v/v in Binding
Buffer) were added, and the plates incubated for 30 min
with moderate agitation. The resin was then washed
with Binding Buffer, and the purified IgG eluted (0.5 M
acetic acid, pH 2.5) and neutralized (1 M ammonium
bicarbonate, pH 7–8.5). The elutions containing the
purified antibody were dried overnight.
In gel block immobilization
The dried samples were reduced with a solution contain-
ing 13.88 mM sodium dodecyl sulfate (SDS), 12.5 mM
Tris (pH 6.6) and 0.05 M dithiothreitol (DTT) for
15 min at 65°C; and alkylated with 100 mM iodoaceta-
mide (IAA) for 30 min in the dark. Then, gel blocks
were formed by adding a mixture of 22.5 μL of Protogel
30%, 11.25 μL of 1.5 M Tris (pH 8.8), 1 μL of 35 mM
SDS, and 1 μL of 34.7 mM ammonium peroxisulphate
solution (APS), and finally adding 1 μL of tetramethy-
lethylenediamine (TEMED) to the samples, letting set
for 15 min. The in gel block immobilization of the glyco-
protein allows an easier removal of the reducing and al-
kylating agents, as well as of buffers and environmental
contaminants, increasing the efficacy of the enzymatic
release of the monosaccharides.
N-glycan release and fluorescent labeling
Each gel block was cut into small pieces (≈ 2 mm2),
washed alternately with acetonitrile and 20 mM sodium
bicarbonate (pH 7), and dried in a vacuum centrifuge.
For the release of N-linked glycans, the dried gel pieces
were incubated for 15 min in 50 μL of a PNGase F (Pro-
zyme) solution (4% v/v in 20 mM sodium bicarbonate
(pH 7)), and a further 12–16 h at 37°C after adding extra
50 μL of 20 mM sodium bicarbonate. The supernatant
was then removed (13,000 rpm, 5 min), and the samples
subjected to a series of washes with water and aceto-
nitrile, with a 15 min sonication for each wash. The
supernatants obtained were collected and dried in a vac-
uum centrifuge. The dried samples were redissolved in
20 μL formic acid (1%), incubated for 40 min at room
temperature and dried in a vacuum centrifuge.
The released N-glycans were labeled for fluorescent
detection using the LudgerTagTM 2-aminobenzamide
(2AB) Glycan Labeling Kit (Ludger), according to manu-
facturer instructions. Briefly, 5 μL of the 2AB labeling
mix were added to each dried glycan sample, incubated
30 min at 65°C, vortexed, spun down, and incubated for
further 90 min.
The excess 2AB label from labeled N-glycans was
cleaned-up using Normal Phase 1 PhyNexus tips (Phy-
Nexus). Briefly, samples were diluted in 95 μL water and
900 μL acetonitrile. The PhyNexus tips were prepared
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by a series of ten uptake washes with 95% acetonitrile
(v/v in water), 20% acetonitrile (v/v in water) and again
95% acetonitrile. Samples were loaded into the Phy-
Nexus tips through ten in-out cycles, followed by ten
uptake washes with 95% acetonitrile. The glycans were
then eluted with five uptake rounds of 20% acetonitrile,
and the elutions collected and dried in a vacuum
centrifuge.
Normal phase-high performance liquid chromatography
For normal phase-high performance liquid chromatog-
raphy (NP-HPLC), each dried sample was ressuspended
in 20 μL water and 80 μL acetonitrile. NP-HPLC was
performed using a TSKgel Amide-80 3 μm (150 ×
4.6 mm) column (Tosoh Bioscience) for 60 min runs, at
30°C, using 50 mM ammonium formate as Solvent A
and acetonitrile as Solvent B. The runs were performed
on a 2695 Alliance separations module (Waters) with a
2475 multi-wavelenght fluorescence detector (Waters),
with excitation and emission wavelengths at 330 and
420 nm, respectively. Conditions of the 60 min method
were a linear gradient of 35 to 47% Solvent A over
48 min at a flow rate of 0.48 mL/min, followed by a min
at 47 to 100% Solvent A and 4 min at 100% Solvent A,
returning to 35% solvent A over 1 min and then finish-
ing with 35% solvent A for 6 min.
The systems were calibrated by running an external
standard of 2-AB dextran ladder (2-AB labeled glucose
homopolymer) alongside the sample runs.
Processing of samples
A fifth-order polynomial distribution curve was fitted to
the dextran ladder and used to allocate glucose unit
(GU) values from retention times, using Empower GPC
software (Waters). Tentative assignment of structures to
the peaks was then made by matching the GU values
obtained with those in GlycoBase (http://glycobase.nibrt.
ie/), and using the known IgG1 profile as a guide. The
relative percentage of N-linked glycans was then calcu-
lated for agalactosylated (G0), monogalactosylated (G1),
digalactosylated (G2), trigalactosylated (G3), galactosy-
lated (G1+G2+G3), core fucosylated (F), core fucosylated
agalactosylated (FG0), core fucosylated monogalactosy-
lated (FG1), core fucosylated digalactosylated (FG2), core
fucosylated trigalactosylated (FG3), monosialylated (S1),
disialylated (S2), trisialylated (S3), sialylated (S1+S2+S3),
monosialylated monogalactosylated (S1G1), monosialy-
lated digalactosylated (S1G2), monosialylated trigalacto-
sylated (S1G3) disialylated digalactosylated (S2G2),
disialylated trigalactosylated (S2G3), trisialylated trigalac-
tosylated (S3G3), high mannose, and complex glycan
structures. The relative percentages were determined by
summing the percentage of area of the peaks pertaining
to each of the abovementioned structures.
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